

# Drug Policy:

## Pomalyst™ (pomalidomide)

<b>POLICY NUMBER</b> UM ONC_1239	<b>SUBJECT</b> Pomalyst™ (pomalidomide)		<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 OF 3</b>
<b>DATES COMMITTEE REVIEWED</b> 04/10/13, 07/24/14, 12/18/15, 12/21/16, 11/08/17, 10/10/18, 09/11/19, 12/11/19, 03/11/20, 05/13/20, 07/08/20, 04/14/21, 11/15/21, 04/13/22, 05/11/22, 04/12/23, 04/10/24	<b>APPROVAL DATE</b> April 10, 2024	<b>EFFECTIVE DATE</b> April 26, 2024	<b>COMMITTEE APPROVAL DATES</b> 04/10/13, 07/24/14, 12/18/15, 12/21/16, 11/08/17, 10/10/18, 09/11/19, 12/11/19, 03/11/20, 05/13/20, 07/08/20, 04/14/21, 11/15/21, 04/13/22, 05/11/22, 04/12/23, 04/10/24	
<b>PRIMARY BUSINESS OWNER:</b> UM		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee		
<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>		
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid	

### I. PURPOSE

To define and describe the accepted indications for Pomalyst (pomalidomide) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

### II. INDICATIONS FOR USE/INCLUSION CRITERIA

#### A. Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

#### B. AIDS Related Kaposi Sarcoma

1. The member has AIDS-related Kaposi sarcoma that has relapsed or is refractory to first line systemic therapy, including Doxil (liposomal doxorubicin) **AND**
2. Pomalyst (pomalidomide) will be used as subsequent therapy in combination with HAART-Highly Active Anti-Retroviral therapy.

### C. Multiple Myeloma

1. Pomalyst (pomalidomide) may be used as follows:
  - a. The member has relapsed or refractory multiple myeloma and has failed 2 prior therapies for myeloma including one proteasome inhibitor & one immunomodulatory agent in **ANY** of the following regimens:
    - i. In combination with dexamethasone or corticosteroid equivalent unless there is an intolerance/contraindication to a corticosteroid.
    - ii. In combination with Darzalex (daratumumab) +/- dexamethasone
    - iii. In combination with Cytoxan (cyclophosphamide) +/- dexamethasone
    - iv. In combination with Empliciti (elotuzumab) +/- dexamethasone
    - v. In combination with Kyprolis (carfilzomib) +/- dexamethasone.
    - vi. In combination with ixazomib +/- dexamethasone
    - vii. In combination with Velcade (bortezomib) +/- dexamethasone
    - viii. In combination with Sarclisa (isatuximab-irfc) +/- dexamethasone
    - ix. In combination with Xpovio (Selinexor) +/- dexamethasone.

### III. EXCLUSION CRITERIA

- A. Disease progression while receiving Pomalyst (pomalidomide) containing regimen.
- B. Dosing exceeds single dose limit of Pomalyst (pomalidomide) 4 mg for Multiple Myeloma and 5 mg for Kaposi Sarcoma.
- C. Treatment exceeds the maximum limit of 105 (1 mg), 42 (2 mg), 21 (3 mg), or 21 (4 mg) capsules per month.
- D. Investigational use of Pomalyst (pomalidomide) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.

7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

#### **IV. MEDICATION MANAGEMENT**

- A. Please refer to the FDA label/package insert for details regarding these topics.

#### **V. APPROVAL AUTHORITY**

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

#### **VI. ATTACHMENTS**

- A. None

#### **VII. REFERENCES**

- A. Ramaswami R, et al. Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clin Cancer Res. 2022 Mar 1;28(5):840-850.
- B. Pomalyst prescribing information. Celgene Corporation. Summit, NJ 2022.
- C. Clinical Pharmacology Elsevier Gold Standard. 2023.
- D. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2023.
- E. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2023.
- F. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2023.
- G. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20;32(12):1277-80.
- H. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.